28237856|t|Wogonin, a plant derived small molecule, exerts potent anti-inflammatory and chondroprotective effects through the activation of ROS / ERK / Nrf2 signaling pathways in human Osteoarthritis chondrocytes
28237856|a|Osteoarthritis (OA), characterized by progressive destruction of articular cartilage, is the most common form of human arthritis. Here, we evaluated the potential chondroprotective and anti-inflammatory effects of Wogonin, a naturally occurring flavonoid, in IL-1β -stimulated human OA chondrocytes and cartilage explants. Wogonin completely suppressed the expression and production of inflammatory mediators including IL-6, COX-2, PGE2, iNOS and NO in IL-1β -stimulated OA chondrocytes. Further, Wogonin exhibits potent chondroprotective potential by switching the signaling axis of matrix degradation from catabolic towards anabolic ends and inhibited the expression, production and activities of matrix degrading proteases including MMP-13, MMP-3, MMP-9, and ADAMTS-4 in OA chondrocytes, and blocked the release of s-GAG and COL2A1 in IL-1β -stimulated OA cartilage explants. Wogonin also elevated the expression of cartilage anabolic factors COL2A1 and ACAN in chondrocytes and inhibited the IL-1β -mediated depletion of COL2A1 and proteoglycan content in the matrix of cartilage explants. The suppressive effect of Wogonin was not mediated through the inhibition of MAPKs or NF-κB activation. Instead, Wogonin induced mild oxidative stress through the generation of ROS and depletion of cellular GSH, thereby modulating the cellular redox leading to the induction of Nrf2 / ARE pathways through activation of ROS / ERK / Nrf2 / HO-1 - SOD2 - NQO1 - GCLC signaling axis in OA chondrocytes. Molecular docking studies revealed that Wogonin can disrupt KEAP-1 / Nrf-2 interaction by directly blocking the binding site of Nrf-2 in the KEAP-1 protein. Genetic ablation of Nrf2 using specific siRNA, significantly abrogated the anti-inflammatory and chondroprotective potential of Wogonin in IL-1β -stimulated OA chondrocytes. Our data indicates that Wogonin exerts chondroprotective effects through the suppression of molecular events involved in oxidative stress, inflammation and matrix degradation in OA chondrocytes and cartilage explants. The study provides novel insights into the development of Nrf2 as a promising candidate and Wogonin as a therapeutic agent for the management of OA.
28237856	0	7	Wogonin	T109	C0251223
28237856	11	16	plant	T002	C0032098
28237856	31	39	molecule	T167	C0567416
28237856	55	72	anti-inflammatory	T080	C1515999
28237856	77	102	chondroprotective effects	T033	C0243095
28237856	115	125	activation	T044	C1148560
28237856	129	132	ROS	T123,T196	C0162772
28237856	135	138	ERK	T116,T126	C0600388
28237856	141	145	Nrf2	T116,T123	C0289507
28237856	146	164	signaling pathways	T044	C0037080
28237856	168	173	human	T016	C0086418
28237856	174	188	Osteoarthritis	T047	C0029408
28237856	189	201	chondrocytes	T025	C0225369
28237856	202	216	Osteoarthritis	T047	C0029408
28237856	218	220	OA	T047	C0029408
28237856	240	251	progressive	T169	C0205329
28237856	252	263	destruction	T052	C1948029
28237856	267	287	articular cartilage,	T024	C0007303
28237856	315	320	human	T016	C0086418
28237856	321	330	arthritis	T047	C0003864
28237856	341	350	evaluated	T058	C0220825
28237856	355	364	potential	T080	C3245505
28237856	365	382	chondroprotective	T033	C0243095
28237856	387	412	anti-inflammatory effects	T080	C1515999
28237856	416	423	Wogonin	T109	C0251223
28237856	427	436	naturally	T169	C0205296
28237856	447	456	flavonoid	T109	C0596577
28237856	461	466	IL-1β	T116,T123	C1702300
28237856	479	484	human	T016	C0086418
28237856	485	487	OA	T047	C0029408
28237856	488	500	chondrocytes	T025	C0225369
28237856	505	514	cartilage	T024	C0007303
28237856	515	523	explants	T074	C0025080
28237856	525	532	Wogonin	T109	C0251223
28237856	544	554	suppressed	T045	C0038855
28237856	559	569	expression	T045	C1171362
28237856	574	584	production	T038	C3714634
28237856	588	610	inflammatory mediators	T121	C0243042
28237856	621	625	IL-6	T116,T123	C1698754
28237856	627	632	COX-2	T116,T126	C1565860
28237856	634	638	PGE2	T109,T121,T125	C0012472
28237856	640	644	iNOS	T116,T126	C0669372
28237856	649	651	NO	T121,T123,T197	C0028128
28237856	655	660	IL-1β	T116,T123	C1702300
28237856	673	675	OA	T047	C0029408
28237856	676	688	chondrocytes	T025	C0225369
28237856	699	706	Wogonin	T109	C0251223
28237856	723	740	chondroprotective	T033	C0243095
28237856	741	750	potential	T080	C3245505
28237856	754	763	switching	T169	C0392747
28237856	768	782	signaling axis	T044	C0037080
28237856	786	804	matrix degradation	T043	C1517052
28237856	810	819	catabolic	T040	C0699900
28237856	828	841	anabolic ends	T038	C0220781
28237856	846	855	inhibited	T080	C0311403
28237856	860	870	expression	T045	C1171362
28237856	872	882	production	T038	C3714634
28237856	887	897	activities	T052	C0441655
28237856	901	917	matrix degrading	T043	C1517052
28237856	918	927	proteases	T116,T126	C1947941
28237856	938	944	MMP-13	T116,T126	C1567335
28237856	946	951	MMP-3	T116,T126	C1723257
28237856	953	958	MMP-9	T116,T126	C0165519
28237856	964	972	ADAMTS-4	T116,T126	C4255123
28237856	976	978	OA	T047	C0029408
28237856	979	991	chondrocytes	T025	C0225369
28237856	997	1004	blocked	T169	C0332206
28237856	1009	1016	release	T169	C0391871
28237856	1020	1025	s-GAG	T109,T121	C0119860
28237856	1030	1036	COL2A1	T116,T123	C1505419
28237856	1040	1045	IL-1β	T116,T123	C1702300
28237856	1058	1060	OA	T047	C0029408
28237856	1061	1070	cartilage	T024	C0007303
28237856	1071	1079	explants	T074	C0025080
28237856	1081	1088	Wogonin	T109	C0251223
28237856	1094	1102	elevated	T080	C3163633
28237856	1107	1117	expression	T045	C1171362
28237856	1121	1130	cartilage	T024	C0007303
28237856	1131	1139	anabolic	T038	C0220781
28237856	1140	1147	factors	T169	C1521761
28237856	1148	1154	COL2A1	T116,T123	C1505419
28237856	1159	1163	ACAN	T116,T123	C1429453
28237856	1167	1179	chondrocytes	T025	C0225369
28237856	1184	1193	inhibited	T080	C0311403
28237856	1198	1203	IL-1β	T116,T123	C1702300
28237856	1214	1223	depletion	T169	C0333668
28237856	1227	1233	COL2A1	T116,T123	C1505419
28237856	1238	1250	proteoglycan	T116,T123	C0033692
28237856	1251	1258	content	T077	C0456205
28237856	1266	1285	matrix of cartilage	T024	C0225371
28237856	1286	1294	explants	T074	C0025080
28237856	1300	1311	suppressive	T045	C0038855
28237856	1312	1318	effect	T080	C1280500
28237856	1322	1329	Wogonin	T109	C0251223
28237856	1359	1369	inhibition	T052	C3463820
28237856	1373	1378	MAPKs	T116,T126	C0752312
28237856	1382	1387	NF-κB	T116,T129	C0079904
28237856	1388	1398	activation	T045	C0599177
28237856	1409	1416	Wogonin	T109	C0251223
28237856	1430	1446	oxidative stress	T049	C0242606
28237856	1459	1476	generation of ROS	T038	C3894443
28237856	1481	1490	depletion	T169	C0333668
28237856	1494	1502	cellular	T025	C0007634
28237856	1503	1506	GSH	T116,T123	C0017817
28237856	1516	1545	modulating the cellular redox	T043	C2754666
28237856	1561	1570	induction	T169	C0205263
28237856	1574	1578	Nrf2	T116,T123	C0289507
28237856	1581	1584	ARE	T114,T123	C3494205
28237856	1585	1593	pathways	T044	C0037080
28237856	1602	1612	activation	T044	C1148560
28237856	1616	1619	ROS	T123,T196	C0162772
28237856	1622	1625	ERK	T116,T126	C0600388
28237856	1628	1632	Nrf2	T116,T123	C0289507
28237856	1635	1639	HO-1	T116,T126	C0538674
28237856	1642	1646	SOD2	T116,T126	C0968147
28237856	1649	1653	NQO1	T116,T126	C1136197
28237856	1656	1660	GCLC	T116,T126	C1522376
28237856	1661	1675	signaling axis	T044	C0037080
28237856	1679	1681	OA	T047	C0029408
28237856	1682	1694	chondrocytes	T025	C0225369
28237856	1696	1721	Molecular docking studies	T170	C3494274
28237856	1736	1743	Wogonin	T109	C0251223
28237856	1748	1755	disrupt	T080	C0332454
28237856	1756	1762	KEAP-1	T116	C3810577
28237856	1765	1770	Nrf-2	T116,T123	C0289507
28237856	1771	1782	interaction	T044	C0872079
28237856	1795	1803	blocking	T169	C0332206
28237856	1808	1820	binding site	T192	C0005456
28237856	1824	1829	Nrf-2	T116,T123	C0289507
28237856	1837	1851	KEAP-1 protein	T116	C3810577
28237856	1853	1860	Genetic	T169	C0314603
28237856	1861	1869	ablation	T061	C0547070
28237856	1873	1877	Nrf2	T028	C1417701
28237856	1893	1898	siRNA	T114,T123	C1099354
28237856	1928	1945	anti-inflammatory	T080	C1515999
28237856	1950	1967	chondroprotective	T033	C0243095
28237856	1968	1977	potential	T080	C3245505
28237856	1981	1988	Wogonin	T109	C0251223
28237856	1992	1997	IL-1β	T116,T123	C1702300
28237856	2010	2012	OA	T047	C0029408
28237856	2013	2025	chondrocytes	T025	C0225369
28237856	2051	2058	Wogonin	T109	C0251223
28237856	2066	2091	chondroprotective effects	T033	C0243095
28237856	2104	2115	suppression	T045	C0038855
28237856	2119	2135	molecular events	T044	C0599845
28237856	2148	2164	oxidative stress	T049	C0242606
28237856	2166	2178	inflammation	T046	C0021368
28237856	2183	2201	matrix degradation	T043	C1517052
28237856	2205	2207	OA	T047	C0029408
28237856	2208	2220	chondrocytes	T025	C0225369
28237856	2225	2234	cartilage	T024	C0007303
28237856	2235	2243	explants	T074	C0025080
28237856	2303	2307	Nrf2	T116,T123	C0289507
28237856	2337	2344	Wogonin	T109	C0251223
28237856	2350	2367	therapeutic agent	T121	C1611640
28237856	2376	2386	management	T058	C0376636
28237856	2390	2392	OA	T047	C0029408